Brasil Pharma sells money-losing unit for $12 mln

Published On 2015-11-12 08:25 GMT   |   Update On 2015-11-12 08:25 GMT

Sao Paulo: Brazilian drugstore chain Brasil Pharma SA sold on Wednesday its money-losing subsidiary Mais Economica to a group of local investors for about 45 million reais (US$12 million) as it tries to return to profitability and cut debt, a source with direct knowledge of the transaction said.Rio de Janeiro-based Verti Capital completed the purchase of Mais Economica on Wednesday afternoon...

Login or Register to read the full article
Sao Paulo: Brazilian drugstore chain Brasil Pharma SA sold on Wednesday its money-losing subsidiary Mais Economica to a group of local investors for about 45 million reais (US$12 million) as it tries to return to profitability and cut debt, a source with direct knowledge of the transaction said.

Rio de Janeiro-based Verti Capital completed the purchase of Mais Economica on Wednesday afternoon in Sao Paulo and the acquisition will be paid over one to three years, said the source, who requested anonymity because the transaction remains private.

The sale of Mais Economica, which operates 188 stores in the Brazilian southern states of Rio Grande do Sul and Parana, gives a respite to BR Pharma, which has struggled to integrate rival chains it has bought since 2009.

BR Pharma is controlled by investment banking firm Grupo BTG Pactual SA and has more than 1,000 drugstores across Brazil. A spokeswoman for BR Pharma did not have an immediate comment.

BR Pharma had a loss of 168.7 million reais in the first six months of 2015, compared with a loss of 328.4 million reais recorded in the same period last year.

The company, which was created after the acquisitions of Rosario, Farmais, Sant'Anna, Big Ben and Mais Economica pharmacy chains, has grappled with integration issues, high debt and rising competition.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News